ALFA FinderBSE filing, NSE: SHAILY. Summary written from the filing by ALFA Finder's alert engine.
Shaily Engineering Plastics Ltd: key numbers
- Share price
- ₹3,147.00
- Market cap
- ₹14,461 Cr
- Revenue (annual)
- ₹990.7 Cr
- Net profit (annual)
- ₹169.9 Cr
- P/E (TTM)
- 77.4×Sector 51.9×
- Promoter holding
- 41.09%+0.00% QoQ
- FII holding
- 19.43%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shaily Engineering Plastics Ltd
All →Shaily Engineering Plastics Merger & Restructuring Worth ₹2.5 Cr
Subsidiary Shaily Medtech Devices was incorporated in Abu Dhabi on November 6, 2026. Initial subscription of AED 10 lakh remains pending.
- Value
- ₹2.50 Cr
Shaily Engineering Plastics Earnings Call Transcript: Key Takeaways
Shaily hits a record quarter as Healthcare becomes its primary engine, contributing 55% of revenue and driving EBITDA margins to a high of 31.9%.
Shaily Engineering Plastics Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs 319.5 Cr (+24%), EBITDA Rs 101.8 Cr (31.9% margin), PAT Rs 61.3 Cr (+20%). Healthcare (+78%) drives growth; GLP-1 capacity and Abu Dhabi facility expansion underway.
Shaily Engineering Plastics Employee Stock Options
Shaily Engineering Plastics allotted 1,300 equity shares to employees on exercise of ESOPs at Rs. 732 per share under its 2019 plan. Issued paid-up capital rises to 4,59,96,548 shares of Rs. 2 each.
Shaily Engineering Plastics Q2 FY27 Results: Net Profit ₹61.3 Cr, Up 19.7% YoY
Shaily Engineering Plastics Ltd reported revenue from operations of ₹319.5 Cr (+24.5% YoY) and net profit of ₹61.3 Cr (+19.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹61.3 Cr · +19.7% YoY
Shaily Engineering Plastics Board Meeting Date
Shaily Engineering Plastics will hold a board meeting on 29th October 2026 to consider unaudited standalone and consolidated financial results for the quarter ended September 2026.
Other product launch announcements
All →Jeena Sikho Lifecare Product Launch
Jeena Sikho Lifecare launched ten new Ayurvedic healthcare products in the domestic market on November 11, 2026. The filing gives product-wise details under SEBI product-launch disclosure rules.
HCL Technologies Product Launch
HCLTech launched a pre-configured semiconductor PLM solution built on PTC Windchill, developed in collaboration with PTC. The release states no contract value or deal size, and the launch is a new product offering.
Morepen Laboratories Product Launch
Morepen launched Desloratadine Tablets USP 5 mg, its first US prescription generic, through subsidiary Morepen Bio Inc. It also filed a Sitagliptin ANDA with the US FDA.
AstraZeneca Pharma India Product Launch
AstraZeneca Pharma India will launch Datverzo, Datopotamab Deruxtecan, in India in November 2026. The drug holds DCGI import and market permission for HR-positive, HER2-negative breast cancer.
Raama Finance Product Launch
Raama Finance launched 'Rupya Lelo', a digital lending platform offering instant personal loans, on October 6, 2026. The product is available only in India, and no loan amount or financial figure is disclosed.
Puravankara Product Launch
Puravankara will launch the residential project Purva Cityspire Phases 1, 2 and 3 in Ernakulam on 15 November 2026. The project is RERA-registered and is being developed by two wholly owned subsidiaries.